OxSonics, a medtech firm developing ultrasound therapies launched out of Oxford University in July last year, has secured £2.7m ($4.49m) in a venture round led by venture firm Longwall Venture Partners.
The UK-based company’s technology uses ultrasound devices combined with ultrasound-sensitive nanoparticles, which can provide real-time feedback to a clinician about whether drug delivery or surgery is successful. OxSonics’ primary targets for the technology are cancer and back pain therapies.
Constantin Coussios, OxSonics’ co-founder, explained: “What we discovered is that…
